Erasca Inc. (ERAS)
NASDAQ: ERASHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ERAS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.78B
- EPS (TTM)
- -$0.97
- Dividend yield
- None
- 52-week range
- 2.81 – 24.28
- Day range
- 13.13 – 14.31
- Volume / Avg
- 11.07M / 5.27M
- Beta
- —
- Shares outstanding
- 350.96M
52-week range
ERAS stock today
Shares of Erasca (ERAS) finished lower on Nov 20 at $13.61, a drop of 4.29% or $0.61 per share, versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 11.07M shares, a sign of unusually heavy trading. Shares are 43.9% below their 52-week high of $24.28, set on Apr 23, 2026 and 384.3% above the 52-week low of $2.81, in the middle of the past year's range.
ERAS is up 265.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 366.1%. Erasca has posted a net loss over the last twelve months (EPS of -$0.97), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Erasca
Company profileErasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jonathan E. Lim M.D.
- Headquarters
- San Diego, CA
- Employees
- 103
- IPO year
- 2021
- Website
- erasca.com
Financial highlights
Full financialsErasca reported a net loss of $124.5 million, compared with a loss of $161.7 million a year earlier. Diluted earnings per share came in at -$0.44.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-124.55M | $-161.65M | $-125.04M | $-242.81M | $-122.76M |
| EPS (diluted) | $-0.44 | $-0.69 | $-0.83 | $-1.99 | $-1.85 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$24.11+77.15%
- Strong buy 2
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.15 vs $-0.14
- Surprise
- -7.14%
ERAS news
All ERAS news- Erasca Throws Down A Gauntlet — And Revolution Throws It Right BackInvestor's Business Daily
- Erasca falls 5% as early RAS cancer data leave key questions unansweredInvesting.com
- Erasca, Inc. Announces Phase 1 Data for ERAS-0015 and Accelerates Phase 3 Trial in Pancreatic Cancer to First Half of 2027NasdaqERAS, BF.A
- Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015GlobeNewswire
- Bristol to evaluate navlimetostat in combination with Erasca assetSeeking Alpha
- Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic CancerNasdaqBMY, ERAS, LEN.B
- Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with NavlimetostatGlobeNewswire
- Why is Erasca stock sliding today?Investing.com
Erasca peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DNTHDianthus Therapeutics Inc. | 84.55 | -0.33% | $4.76B | vs ERAS |
| PTCTPTC Therapeutics Inc. | 56.42 | -3.27% | $4.71B | vs ERAS |
| LQDALiquidia Corporation | 54.43 | -3.88% | $4.90B | vs ERAS |
| COGTCogent Biosciences Inc. | 26.72 | -3.69% | $4.65B | vs ERAS |
| TVTXTravere Therapeutics Inc. | 47.00 | -2.69% | $4.51B | vs ERAS |
| MANEVeradermics Incorporated | 119.52 | -3.92% | $5.04B | vs ERAS |
| IONSIonis Pharmaceuticals Inc. | 26.58 | -2.35% | $4.43B | vs ERAS |
| BLTEBelite Bio Inc ADR | 127.38 | -15.65% | $5.17B | vs ERAS |
Indexes, lists and sector
Erasca stock FAQ
What is Erasca's stock price today?
ERAS last traded at $13.61 as of Nov 20, 4:00 PM EST, down 4.29% on the day. Prices are delayed at least 15 minutes.
Who is Erasca's CEO?
Dr. Jonathan E. Lim M.D. is the chief executive officer of Erasca Inc., which has about 103 employees.
What is the ERAS 52-week high?
The 52-week high for ERAS is $24.28 and the 52-week low is $2.81. The stock is currently 43.9% below its high.